Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Epic Sciences closes $40mm Series D round

Executive Summary

Cancer diagnostics firm Epic Sciences Inc. raised $40mm through its Series D round from investors including Hermed Capital (lead), Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Ltd., RMI Partners (RusnanoMedInvest), Sabby Capital, and VI Ventures. Proceeds will support test development and will also help the firm enhance its No Cell Left Behind platform for circulating tumor cell detection and characterization.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies